Format

Send to

Choose Destination
J Allergy Clin Immunol. 2017 Jan;139(1):66-71.e3. doi: 10.1016/j.jaci.2016.01.055. Epub 2016 Apr 21.

Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.

Author information

1
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn.
2
Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn.
3
Kaiser Permanente Medical Care Program, Perinatal Research Unit, Division of Research, Oakland, Calif; Kaiser Permanente, Perinatal Research Unit, Division of Research, Oakland, Calif; Department of Inpatient Pediatrics, Kaiser Permanente Medical Center, Walnut Creek, Calif.
4
Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn.
5
Kaiser Permanente, Perinatal Research Unit, Division of Research, Oakland, Calif.
6
Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn.
7
Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn; Brigham Young University, Provo, Utah.
8
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma and Environmental Health Sciences Research, Vanderbilt University School of Medicine, Nashville, Tenn. Electronic address: tina.hartert@vanderbilt.edu.

Abstract

BACKGROUND:

Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma development. RSV immunoprophylaxis during infancy is efficacious in preventing RSV-related hospitalizations and has been associated with decreased wheezing in the first years of life.

OBJECTIVE:

We investigated whether greater adherence to immunoprophylaxis in infants at high risk for severe RSV would be associated with decreased childhood asthma.

METHODS:

We conducted a retrospective cohort investigation including children born from 1996-2003 who were enrolled in Kaiser Permanente Northern California or Tennessee Medicaid and eligible to receive RSV immunoprophylaxis. Asthma was defined at 4.5 to 6 years of age by using asthma-specific health care visits and medication fills. We classified children into immunoprophylaxis eligibility groups and calculated adherence (percentage receipt of recommended doses). We used a set of statistical strategies (multivariable logistic regression and propensity score [PS]-adjusted and PS-matched analyses) to overcome confounding by medical complexity because infants with higher adherence (≥70%) have higher prevalence of chronic lung disease, lower birth weight, and longer nursery stays.

RESULTS:

By using multivariable logistic regression and PS-adjusted models in the combined group, higher adherence to RSV immunoprophylaxis was not associated with decreased asthma. However, in PS-matched analysis, treated children with 70% or greater adherence had decreased odds of asthma compared with those with 20% or less adherence (odds ratio, 0.62; 95% CI, 0.50-0.78).

CONCLUSIONS:

This investigation of RSV immunoprophylaxis in high-risk children primarily found nonsignificant associations on prevention of asthma in specific preterm groups. Our findings highlight the need for larger studies and prospective cohorts and provide estimates of potential preventive effect sizes in high-risk children.

KEYWORDS:

Respiratory syncytial virus; asthma; bronchiolitis; lower respiratory tract infection; palivizumab; primary prevention; respiratory syncytial virus immunoprophylaxis; wheezing

PMID:
27212083
PMCID:
PMC5074917
DOI:
10.1016/j.jaci.2016.01.055
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center